Skip to Main Content

Paper Details

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
24
2023
Author NameAffiliation
Rossella E NappiUniversity of Pavia, and Research Center for Reproductive Medicine and Gynecological Endocrinology - Menopause Unit, Fondazione Policlinico IRCCS S. Matteo
Petra Stute
Wendy WolfmanUniversity of Toronto
Nanette SantoroUniversity of Colorado School of Medicine
  • 1 - 4

Datasets

Release 1.2